CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from…
Category: Business
National Vision Holdings, Inc. Reports Third Quarter 2024 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the third quarter ended September 28, 2024. “We are encouraged by the progress we are making agains…
National Vision Completes Comprehensive Review of Store Fleet
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced the results of its comprehensive store fleet review. In August 2024, the Company announced it had identified an initial list…
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announce…
Georgia State Parks Introduce Free Colorblind-Adapting Glasses at Cloudland Canyon, Sweetwater Creek and Skidaway Island
ATLANTA–(BUSINESS WIRE)– #enchroma–Georgia’s State Parks continue to enhance accessibility in new and innovative ways, with the latest addition being EnChroma colorblind glasses at three of its most popular destinations: Cloudland Canyon, Sweetwater…
poLight ASA Delivers the ‘Human Eye Experience’ at CES 2025
HORTEN, Norway–(BUSINESS WIRE)– #AR–poLight ASA (OSE: PLT) will demo its tunable optics technology delivering ‘the human eye experience’ at CES®, Jan. 7-10, 2025 in Las Vegas, Nevada.
LumiThera obtient l'agrément de la FDA pour son traitement Valeda, qui améliore la vision des patients atteints de DMLA sèche
SEATTLE–(BUSINESS WIRE)–LumiThera Inc. est une société spécialisée dans les dispositifs médicaux qui propose un traitement par photobiomodulation (PBM) des lésions et maladies oculaires ; elle a annoncé aujourd’hui que la FDA (Food & Drug Adminis…
Riassunto: LumiThera ottiene l’autorizzazione della FDA al trattamento con Valeda per pazienti affetti dalla forma atrofica della AMD per migliorare la funzionalità visiva
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., produttore di dispositivi medici che offre un trattamento di fotobiomodulazione (PBM) per patologie e lesioni oculari, oggi ha annunciato che l’agenzia federale statunitense per gli alimenti e i farmaci (FDA) h…
Resumen: La empresa LumiThera obtiene la autorización de la FDA para el tratamiento Valeda para mejorar la visión en pacientes con DMAE seca
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., una empresa de dispositivos médicos que ofrece tratamiento de fotobiomodulación (PBM) para enfermedades y daños oculares, anunció hoy que la Administración de Alimentos y Medicamentos de EE.UU. (FDA) ha autoriz…
Samenvatting: LumiThera verkrijgt FDA-autorisatie voor Valeda-behandeling voor droge AMD-patiënten om het zicht te verbeteren
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., een medisch apparaatbedrijf dat fotobiomodulatie (PBM)-behandelingen aanbiedt voor oculaire schade en ziekte, heeft vandaag aangekondigd dat de Amerikaanse Food & Drug Administration (FDA) de marketing van …
LumiThera erhält FDA-Zulassung für Valeda-Behandlung zur Verbesserung der Sehkraft bei trockener AMD
SEATTLE–(BUSINESS WIRE)–LumiThera Inc., ein Unternehmen für medizinische Geräte, das photobiomodulatorische (PBM) Behandlungen für Augenschäden und -erkrankungen anbietet, gab heute bekannt, dass die US-amerikanische Food & Drug Administration (F…
LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera, Inc. today announced the U.S. FDA has authorized marketing of Valeda® Light Delivery System for patients with dry AMD.
Glaukos Announces Third Quarter 2024 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financ…
FELIQS Receives U.S. FDA Fast Track Designation for FLQ-101, a First-in-class Small Molecule to Prevent Retinopathy of Prematurity
FUKUOKA, Japan & NEW YORK–(BUSINESS WIRE)–FELIQS®, a clinical stage multinational biopharmaceutical company focused on the development of first-in-class small molecules targeting lipid oxidation, announced today that the U.S. Food and Drug Administra…
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions Bid…
Lumicell’s LumiSystem™ Featured on Viewpoint with Dennis Quaid for New Episode on Fluorescence-Imaging Guidance During Lumpectomy Surgery
NEWTON, Mass.–(BUSINESS WIRE)– #LUMISIGHT–Lumicell’s LumiSystem™ Featured on Viewpoint with Dennis Quaid for New Episode on Fluorescence-Imaging Guidance During Lumpectomy Surgery
Get Hooked on Maui Jim’s New Fishing Style, Keha
PEORIA, Ill.–(BUSINESS WIRE)–Maui Jim set sail on a fishing adventure with the launch of its first activity-specific performance-inspired sport style, Keha 663 and its Asian Fit counterpart Keha Asian Fit 664, on October 8. This quintessential 8-base…
Ora renforce son leadership mondial avec des nominations clés en Europe et dans les services aux personnes
BOSTON–(BUSINESS WIRE)–Ora, leader mondial de la recherche sous contrat en ophtalmologie, a le plaisir d’annoncer les nominations de Marcin Ernst, MD, MBA, au poste de vice-président pour l’Europe, et de Tim Neathery au poste de directeur des ressour…
Riassunto: Ora rafforza la dirigenza globale con nomine chiave in Europa e in People Services
BOSTON–(BUSINESS WIRE)–Ora, la principale azienda di ricerca clinica su contratto (CRO) nel settore oftalmico a livello globale, è lieta di annunciare le nomine di Marcin Ernst, MD, MBA e di Tim Neathery al ruolo, rispettivamente, di Vicepresidente p…
Ora verstevigt haar wereldleiderschap dankzij belangrijke benoemingen in Europa en People Services
BOSTON–(BUSINESS WIRE)–Ora, de toonaangevende internationale CRO (contract research organization) actief in oftalmologie, kondigt met genoegen de benoemingen aan van Marcin Ernst, MD, MBA, tot vicevoorzitter voor Europa, en van Tim Neathery tot Chief…